Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 3, 2013, Pages 339-344

  Miller, Darlene ^a   Chang, Jonathan S ^a   Flynn, Harry W ^a   Alfonso, Eduardo C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BESIFLOXACIN; CIPROFLOXACIN; GENTAMICIN; MOXIFLOXACIN; OXACILLIN; TRIMETHOPRIM; VANCOMYCIN;

ARTICLE; BLEPHARITIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE EFFECTIVENESS; CONJUNCTIVITIS; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SENSITIVITY; ENDOPHTHALMITIS; HUMAN; IN VITRO STUDY; KERATITIS; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; AZEPINES; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 84874958092     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0081     Document Type: Article

References (27)

1. Marangon, F.B., et al. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am. J. Ophthalmol. 137:453-458, 2004. (Pubitemid 38328635)
2. Au, Y.K., et al. Coagulase-negative staphylococci in conjunctivitis and blepharitis. Yan Ke Xue Bao. 9:129-135, 1993.
3. Afshari, N.A., et al. Trends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitis. J. Ocul. Pharmacol. Ther. 24:217-223, 2008. (Pubitemid 351450474)
4. Forster, W., et al. Methicillin-resistant Staphylococcus aureus keratitis after excimer laser photorefractive keratectomy1. J. Cataract. Refract. Surg. 28:722-724, 2002. (Pubitemid 34286798)
5. Solomon, R., et al. Methicillin-resistant Staphylococcus aureus infectious keratitis following refractive surgery. Am. J. Ophthalmol. 143:629-634, 2007. (Pubitemid 46463939)
6. Miller, D., et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch. Ophthalmol. 124:479-483, 2006.
7. Bagga, B., Reddy, A.K., and Garg, P. Decreased susceptibility to quinolones in methicillin-resistant Staphylococcus aureus isolated from ocular infections at a tertiary eye care centre. Br. J. Ophthalmol. 94:1407-1408, 2010.
8. Bertino, J.S. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin. Ophthalmol. 3:507-521, 2009.
9. Schubert, T.L., Hume, E.B., and Willcox, M.D. Staphylococcus aureus ocular isolates from symptomatic adverse events: antibiotic resistance and similarity of bacteria causing adverse events. Clin. Exp. Optom. 91:148-155, 2008.
10. Ta, C.N., et al. Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ophthalmology. 110:1946-1951, 2003. (Pubitemid 37163312)
11. Asbell, P.A., et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am. J. Ophthalmol. 145:951-958, 2008.
12. Asbell, P.A., et al. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J. Cataract. Refract. Surg. 34:814-818, 2008. (Pubitemid 351615511)
13. Carter, N.J., and Scott, L.J. Besifloxacin ophthalmic suspension 0.6%. Drugs. 70:83-97, 2010.
14. Zhang, J.Z., and Ward, K.W. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J. Antimicrob. Chemother. 61:111-116, 2008.
15. Haas, W., et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 53:3552-3560, 2009.
16. Haas, W., et al. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J. Antimicrob. Chemother. 65:1441-1447, 2010.
17. Chang, M.H., and Fung, H.B. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. Clin. Ther. 32:454-471, 2010.
18. Comstock, T.L., et al. Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis. Clin. Ophthalmol. 4:215-225, 2010.
19. McDonald, M.B., et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 116:1615-1623, e1, 2009.
20. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. Twentieth Informomational Supplement. Wayne, Pennsylvania: CLSI; 2010; p. 1-151.
21. Proksch, J.W., et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J. Ocul. Pharmacol. Ther. 25:335-344, 2009.
22. Torkildsen, G., et al. Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. Clin. Ophthalmol. 4:331-341, 2010.
23. Ambrose, P.G., et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797, 2001. (Pubitemid 32906673)
24. Wise, R., and Honeybourne, D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur. Respir. J. 14:221-229, 1999. (Pubitemid 29411262)
25. Wright, D.H., et al. Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions. Antimicrob. Agents Chemother. 46:1561-1563, 2002. (Pubitemid 34415345)
26. Haas, W., et al. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin. Ophthalmol. 5:1369-1379, 2011.
27. Haas, W., et al. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2011 surveillance study. Am. J. Ophthalmol. 152:567-574.e3, 2011.